A new member has been added to the Fitbit Charge Family namely the Fitbit Charge 3 with an additional feature of measuring the SpO2. The new version will hit the market in October.

 “With Charge 3, we are building on the success of our best-selling Charge franchise and delivering our most innovative tracker, offering an extremely slim, comfortable, and premium design, along with the advanced health and fitness features our users want. Charge 3 gives existing users a compelling reason to upgrade, while also allowing us to reach new users who want a sleeker, more affordable wearable in a tracker form factor,” CEO Fitbit James Park said in a statement.

The new version claims to identify indicators of allergies, asthma, or sleep apnea with its relative SpO2 tracker which enables the device to assess variations in blood oxygenation levels and spot breathing abnormalities. As included in its Pre-Cert pilot, aiming to develop FDA-monitored software for illnesses like sleep apnea and atrial fibrillation, Fitbit has kept its work with the FDA as per its commitment during its release.

"Fitbit continues to harness its data to give users actionable insights into their health and wellness. For example, we've found that one in four people get significantly more sleep on weekends than weekdays, which implies they are trying to make up for reduced sleep during the week,” Shelton Yuen, VP of research at Fitbit, said in a statement.

Features of Charge 3 include water resistance to 50 meters, GPS and run detection, augmented accuracy in heart rate calculation, and an access into Fitbit’s society-oriented community functions. It will soon feature a dashboard that acts as a window to viewers into values like hydration, sleep, weight, and female health tracking displayed on the screen of Charge 3.